Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H34O5 |
Molecular Weight | 354.481 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
InChI
InChIKey=GMVPRGQOIOIIMI-DWKJAMRDSA-N
InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1
Molecular Formula | C20H34O5 |
Molecular Weight | 354.481 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:13:54 UTC 2023
by
admin
on
Fri Dec 15 15:13:54 UTC 2023
|
Record UNII |
F5TD010360
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type |
---|
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
G04BE01
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
||
|
NDF-RT |
N0000175454
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
||
|
NDF-RT |
N0000007706
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
||
|
LOINC |
12837-1
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
||
|
LOINC |
14005-3
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
||
|
WHO-VATC |
QC01EA01
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
||
|
FDA ORPHAN DRUG |
70092
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
||
|
NDF-RT |
N0000007706
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
||
|
NDF-RT |
N0000180189
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
||
|
LOINC |
70092-2
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
||
|
FDA ORPHAN DRUG |
88795
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
||
|
WHO-VATC |
QG04BE01
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
||
|
NDF-RT |
N0000009059
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
||
|
NDF-RT |
N0000007706
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
||
|
NDF-RT |
N0000009911
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
||
|
LOINC |
2852-2
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
||
|
NCI_THESAURUS |
C78568
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
||
|
FDA ORPHAN DRUG |
95596
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
||
|
NDF-RT |
N0000000106
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
||
|
WHO-ATC |
C01EA01
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
||
|
LOINC |
70093-0
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
F5TD010360
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | |||
|
15544
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | |||
|
DTXSID9022578
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | |||
|
745-65-3
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | |||
|
138
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | |||
|
CHEMBL495
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | |||
|
1016000
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | |||
|
165559
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | |||
|
m9257
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | Merck Index | ||
|
4425
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | |||
|
PROSTAGLANDIN E1
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | |||
|
DB00770
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | |||
|
C28816
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | |||
|
N0000009059
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | Genitourinary Arterial Vasodilation [PE] | ||
|
F5TD010360
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | |||
|
1882
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | |||
|
15551
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | |||
|
N0000009911
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | Venous Vasodilation [PE] | ||
|
57397
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | |||
|
SUB05372MIG
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | |||
|
5280723
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | |||
|
212-017-2
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | |||
|
D000527
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | |||
|
598
Created by
admin on Fri Dec 15 15:13:54 UTC 2023 , Edited by admin on Fri Dec 15 15:13:54 UTC 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
||
|
SUB_CONCEPT->SUBSTANCE |
|
||
|
TARGET -> AGONIST | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST | |||
|
DERIVATIVE -> PARENT |
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
15-keto-PGE1 has only been detected in vitro in homogenized lung preparations; 15-keto metabolites are less pharmacologically active than the parent compound
IN-VITRO
|
||
|
METABOLITE -> PARENT |
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT |
13,14-dihydro-15-ketoprostaglandin E1 is pulmonary metabolite of PGE1 in dogs.
MAJOR
PLASMA
|
||
|
PRODRUG -> METABOLITE ACTIVE | |||
|
METABOLITE -> PARENT |
15-keto metabolites are less pharmacologically active than the parent compound in vitro using isolated animal organs.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
test 1
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
test 1
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||